Recurrent melanoma may be more common than previously thought

April 17, 2006

Approximately 8 percent of patients with melanoma skin cancer may develop an additional melanoma within two years of their initial diagnosis, and those with atypical moles appear to be at higher risk, according to an article in the April issue of Archives of Dermatology, one of the JAMA/Archives journals.

Cutaneous (skin) melanoma begins in cells known as melanocytes, which produce the pigment that gives skin its color. Previous studies have evaluated the recurrence of melanoma among patients already diagnosed with the disease; most have estimated that less than 4 percent of them will develop additional tumors in the year following diagnosis, according to background information in the article.

Linda Titus-Ernstoff, Ph.D., Dartmouth Medical School, Lebanon, N.H., and colleagues assessed the frequency of and risk factors for recurring cancer among 354 New Hampshire residents with a first diagnosis of cutaneous melanoma. Participants completed a 40-minute telephone interview, during which they answered questions about medical history, demographics, eye and hair color, sun exposure and whether their skin tanned, burned or freckled in the sun. They then underwent a skin examination, during which a physician identified and catalogued benign and atypical moles. Atypical moles have at least three of the following features: a diameter larger than 5 millimeters, redness, an irregular or ill-defined border, a variety of colors or a portion that is flat.

By examining pathology records, the researchers found that 20 (6 percent) of the participants developed an additional melanoma within one year of diagnosis and 27 (8 percent) developed an additional melanoma within two years. Sixty-three percent of those who developed additional tumors and 37 percent of those who did not had at least one atypical mole. The more atypical moles an individual had, the more likely he or she was to develop additional melanomas--three or more atypical moles indicated four times the risk. Lifetime history of sun exposure did not appear to influence the risk of recurring melanoma. However, those with a history of sunburn were less likely to develop a second melanoma than those without, a finding that "must be viewed cautiously," the researchers write. Those who are predisposed to develop multiple melanomas may be less susceptible to sunburn than those with one melanoma, or they may be more likely to avoid sun exposure. "In any case, the association should not be construed as suggesting that sunburn protects patients with melanoma from developing additional tumors," the authors continue.

"The importance of studying risk for additional primary tumors within a defined population-based study group is underscored by our findings," they conclude. "These findings, which indicate a higher frequency of second primary melanomas than suggested by previous studies, also underscore the importance of close surveillance of patients with melanoma."
-end-
(Arch Dermatol. 2006; 142:433-438. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: This project was supported by a grant from the National Cancer Institute, Bethesda, Md.

The JAMA Network Journals

Related Melanoma Articles from Brightsurf:

Boosting treatments for metastatic melanoma
University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life.

A promising new tool in the fight against melanoma
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

New targets for melanoma treatment
A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Innovative smartphone-camera adaptation images melanoma and non-melanoma
An article published in the Journal of Biomedical Optics (JBO), ''Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring,'' shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer.

Antihistamines may help patients with malignant melanoma
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma?

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.

Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.

Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.

Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.

Read More: Melanoma News and Melanoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.